Quarterly Result24 Apr 2025, 08:50 pm
Laurus Labs Announces Full Year FY25 Results: Revenues at ₹ 5,554 Cr; EBITDA at ₹ 1,115 Cr, 20% margins
AI Summary
Laurus Labs, a leading research and development driven pharmaceutical and biotech company in India, has announced its Q4 & Full Year FY25 results. The company reported revenues of ₹ 5,554 Cr and EBITDA of ₹ 1,115 Cr, with EBITDA margins at 20.1%. The results demonstrate the strength of the business model and give confidence in the outlook. The company is deepening cooperation with major clients and augmenting it with promising BD and capacity creation. The business remains well positioned to evolve into a well-diversified CMO/CDMO company with a promising pipeline, enabling several technology platforms and commercial excellence.
Key Highlights
- FY25 Revenues ₹ 5,554 Cr and 10% revenue growth
- EBITDA ₹ 1,115 Cr with margin of 20.1%
- Gross margins maintained at healthy levels 55.4%
- CDMO business reported revenues of ₹ 1,374 Cr, increased by 49%
- Bio business reported revenues of ₹ 160 Cr, driven by strong demand in AOF portfolio